There are 37 resources available
LBA95 - Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia: Efficacy and safety in the multinational phase III SCALA program
Presenter: David Currow
Session: Proffered Paper session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Presenter: Kathryn Arbour
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1016O - Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
Presenter: Lukas Flatz
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
LBA67 - A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
Presenter: Myung-Ju Ahn
Session: Proffered Paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer
Presenter: Ze-rui Zhao
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
653O - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
Presenter: Jie Wang
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA2 - ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial
Presenter: Gerard Zalcman
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA1 - CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
Presenter: Tina Cascone
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA64 - Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC
Presenter: Solange Peters
Session: Proffered Paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast